You are here

Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

Last updated on February 20, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Ancenis, , 44150 France
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
13-valent Pneumococcal Vaccine, Immunization, Safety, Antibody Response
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
3 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy subjects at least 3 years of age, who received all 4 assigned doses of
pneumococcal conjugate vaccine and completed Study 6096A1-008-EU (NCT00366678) for at
least 24 months

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Vaccination with any licensed or investigational pneumococcal vaccine since completion
of Study 6096A1-008-EU(NCT00366678).

- History of culture-proven invasive disease caused by S pneumoniae since the completion
of Study 6096A1-008-EU (NCT00366678).

- Previous anaphylactic reaction to any vaccine or vaccine-related component.

- Contraindication to vaccination

NCT01026038
Pfizer
Completed
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

13-valent Pneumococcal Vaccine, Immunization, Safety, Antibody Response
NCT01026038
All Genders
3+
Years
Multiple Sites
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
NCT00743652
All Genders
0+
Years
Multiple Sites
Pediatric Safety and Effectiveness
NCT02554656
All Genders
0+
Years
Osaka,
Phase 1, Single Dose, Safety, Toleration, Pharmacokinetics
NCT01415102
All Genders
18+
Years
Bruxelles,

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now